Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 7/20 | 0.48 |
| ▸ | DHODH | Q02127 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15800320 | 0.88 | PLA2G2A (0.54) | PLA2G2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL15976013 | 0.87 | MCL1 (0.41) | PLA2G2ADHODHMCL1SMN1; SMN2HDAC1 | |
| SCHEMBL15976007 | 0.86 | PLA2G2A (0.50) | PLA2G2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL15976003 | 0.85 | PLA2G2A (0.50) | PLA2G2ADHODHKDM4ESMN1; SMN2 | |
| SCHEMBL110393 | 0.84 | DHODH (0.52) | PLA2G2ADHODHMCL1KDM4EALDH1A1 | |
| SCHEMBL15800322 | 0.81 | PLA2G2A (0.47) | PLA2G2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL15976000 | 0.73 | TACR3 (0.41) | PLA2G2ADHODHKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL15976429 | 0.72 | PLA2G2A (0.57) | PLA2G2ADHODHKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL110395 | 0.72 | PLA2G2A (0.69) | PLA2G2ADHODHKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL15976010 | 0.71 | DHODH (0.41) | PLA2G2ADHODHKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | JAK2, JAK1, JAK3 | PLA2G2A 4509/4885DHODH 3348/4885MCL1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.